Results 121 to 130 of about 20,705 (157)

Real-Life Efficacy of Single-Inhaler Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate in Persistent COPD Users: A Retrospective Database Study. [PDF]

Biomedicines
Sposato B, Lacerenza LG, Croce S, Petrucci E, Fabbrini V, Giannini L, Baratta P, Cresti A, Ricci A, Micheletto C, Perrella A, Alonzi V, Serafini A, Scalese M.   +13 more
europepmc   +1 more source

Real-World Comparative Effectiveness Study in Patients with Asthma Initiating Fluticasone Furoate/Vilanterol or Beclometasone Dipropionate/Formoterol Fumarate in General Practice in England. [PDF]

Adv Ther
Woodcock A, Blakey J, Bourdin A, Canonica GW, Domingo C, Ford A, Hulme R, Tritton T, Palomares I, Sadhu S, Biswas A, Verma M.   +11 more
europepmc   +1 more source

Assessment of Symptoms Control, Pulmonary Function and Related Quality of Life in Asthmatic Patients Treated with Extrafine Beclomethasone Dipropionate/Formoterol Fumarate 100/6 μg pMDI: Results of a Multicenter Observational Study in Romania (ALFRESCO Study). [PDF]

J Asthma Allergy, 2022
Ulmeanu R, Bloju S, Vittos O.
europepmc   +1 more source

Effects of inhaled beclometasone dipropionate/formoterol fumarate/glycopyrronium vs. beclometasone dipropionate/formoterol fumarate and placebo on lung hyperinflation and exercise endurance in chronic obstructive pulmonary disease: a randomised controlled trial. [PDF]

Respir Res
Watz H, Kirsten AM, Ludwig-Sengpiel A, Krüll M, Mroz RM, Georges G, Varoli G, Charretier R, Cortellini M, Vele A, Galkin D.   +10 more
europepmc   +1 more source

Budesonide/glycopyrronium/formoterol fumarate co-suspension metered dose inhaler relieves cough after lobectomy: a randomized controlled study. [PDF]

Transl Lung Cancer Res
Dong J, Jiang S, Qiu Y, Li J, Cui F, Liang H, Lao S, Xie Z, Huang J, Hao Z, He H, Xv X, Zhang M, He M, Zhang Y, He J, Wang W.   +16 more
europepmc   +1 more source

Glycopyrrolate/formoterol fumarate MDI in mild-to-moderate chronic obstructive pulmonary disease (PIONEER): a protocol for a randomised, double-blind, placebo-controlled trial. [PDF]

BMJ Open Respir Res
Wang FY, Wang ZH, Xu JX, Liang ZY, Ran PX, Zhou YM, Gao Y, Shi WJ, Jiang WY, Li YQ, Zhang DY, Chen RC, Guan WJ, Zhong NS, Zheng JP.   +14 more
europepmc   +1 more source

Bioequivalence of budesonide/glycopyrrolate/formoterol fumarate with a next-generation propellant versus hydrofluoroalkane-134a in healthy adults: phase I, randomized, double-blind, single-dose, partial-replicate, three-way cross-over lung exposure and total systemic exposure studies. [PDF]

Ther Adv Respir Dis
Bednarczyk A, Aurivillius M, Jassal M, Shah M, Raphiou I, Petullo D, Xu J, Heijer M, Sychowicz K, Collison K, Silva C, Reddy J, Han D, Goldwater R, Gillen M, Patel M.   +15 more
europepmc   +1 more source

Green Assessment of Sensitive Spectrofluorimetric Methods for Simultaneous Estimation of Formoterol Fumarate and Fluticasone Propionate Using a Micelle-Mediated Approach. [PDF]

J Fluoresc
Adawy HA, Hegazy MA, Saad SS, Boltia SA.
europepmc   +1 more source

Characteristics of Patients Initiated on Budesonide/Glycopyrronium Bromide/Formoterol Fumarate Single Inhaler Triple Therapy for the Treatment of Chronic Obstructive Pulmonary Disease: A Population-Based Observational Study. [PDF]

Int J Chron Obstruct Pulmon Dis
Deslee G, Fabry-Vendrand C, Salmi E, Poccardi N, Coriat A, Ghout I, Eteve-Pitsaer C, Adderley NJ, Leleu H.   +8 more
europepmc   +1 more source

Comparative Effectiveness of Fluticasone Furoate/Umeclidinium/Vilanterol and Budesonide/Glycopyrrolate/Formoterol Fumarate among US Patients with Chronic Obstructive Pulmonary Disease. [PDF]

Adv Ther
Mannino D, Weng S, Germain G, Boudreau J, Tardif-Samson A, Forero-Schwanhaeuser S, Laliberté F, Gravelle P, Compton CH, Noorduyn SG, Paczkowski R.   +10 more
europepmc   +1 more source